

June 10, 2022

## **An update on the medmix Poland manufacturing site**

Dear valued customer,

Over the last weeks we have kept you informed about the sanctions of the Polish government against our Polish manufacturing site.

medmix has appealed the denial of its petition for immediate removal from the sanctions list, which it believes to be erroneous. The appeal was made to the administrative court in Warsaw. Diplomatic and political channels including the Swiss embassy in Poland and the Swiss government administration have continued to extend their collaboration and support to medmix' efforts.

While the situation is currently pending a resolution, we are committed to ensuring that you remain informed of the latest status and related measures to ramp-up production capacities outside of Poland. A high-level summary of some of the targeted actions to mitigate the impact of the sanctions is as follows:

- All shipments in transit have been rerouted to locations outside Poland.
- Reallocation of finished goods worldwide to meet urgent customer requirements.
- Ramped up capacity at our production sites in Haag - Switzerland, Elgin - USA, Shanghai - China.
- Accelerated delivery schedules for injection molding tools and injection molding machines to further enable ramp-up capacity. These new tools and machines are to be installed at other factories within our production network. All needed internal resources and expertise to run production validation processes have been allocated accordingly.
- We are evaluating the feasibility of repurposing some of our predecessor tools to be deployed in the production of our most critical, high-volume products. This is an option which, if feasible, we can mobilize in a short timeframe.


In parallel, an application for release of manufacturing equipment and finished goods at our Wroclaw, Poland site has been submitted to the relevant authorities and is currently pending a decision.

Additional details regarding the specific impact and recovery plan including anticipated timeline for the products relevant to you will be shared by your medmix sales representative in the days and weeks ahead.

We will continue to keep you updated regularly and remain at your disposal for any further questions.

The team remains fully engaged and focused on securing the best outcomes for our valued customers. We thank you for your patience and support in these challenging times.

Sincerely, on behalf of **medmix Switzerland AG**

A handwritten signature in blue ink, appearing to read 'Roman Thönig'.

Roman Thönig  
Head of Business Segment Industry

A handwritten signature in blue ink, appearing to read 'Levi Quinn'.

Levi Quinn  
COO medmix